A detailed history of Capital Research Global Investors transactions in Novartis Ag stock. As of the latest transaction made, Capital Research Global Investors holds 905,435 shares of NVS stock, worth $89.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
905,435
Previous 904,128 0.14%
Holding current value
$89.7 Million
Previous $96.3 Million 8.2%
% of portfolio
0.02%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$106.13 - $120.89 $138,711 - $158,003
1,307 Added 0.14%
905,435 $104 Million
Q2 2024

Aug 13, 2024

SELL
$92.57 - $107.37 $555 - $644
-6 Reduced -0.0%
904,128 $96.3 Million
Q1 2024

May 14, 2024

BUY
$95.27 - $108.47 $39,251 - $44,689
412 Added 0.05%
904,134 $87.5 Million
Q4 2023

Feb 13, 2024

BUY
$92.27 - $101.54 $9,688 - $10,661
105 Added 0.01%
903,722 $91.2 Million
Q3 2023

Nov 13, 2023

BUY
$94.73 - $105.13 $35,429 - $39,318
374 Added 0.04%
903,617 $92 Million
Q2 2023

Aug 11, 2023

BUY
$92.52 - $104.91 $37,748 - $42,803
408 Added 0.05%
903,243 $91.1 Million
Q1 2023

May 15, 2023

SELL
$80.03 - $92.81 $6.53 Million - $7.57 Million
-81,573 Reduced 8.29%
902,835 $83.1 Million
Q3 2022

Nov 14, 2022

SELL
$74.61 - $87.26 $25,591 - $29,930
-343 Reduced 0.03%
984,408 $74.8 Million
Q2 2022

Aug 15, 2022

SELL
$80.52 - $93.75 $29,228 - $34,031
-363 Reduced 0.04%
984,751 $83.2 Million
Q1 2022

May 16, 2022

BUY
$80.11 - $90.62 $6.61 Million - $7.47 Million
82,458 Added 9.14%
985,114 $86.4 Million
Q4 2021

Feb 14, 2022

SELL
$79.7 - $88.13 $30,604 - $33,841
-384 Reduced 0.04%
902,656 $79 Million
Q3 2021

Nov 15, 2021

BUY
$81.78 - $95.14 $26,169 - $30,444
320 Added 0.04%
903,040 $73.9 Million
Q2 2021

Aug 16, 2021

SELL
$85.24 - $94.15 $125 Million - $138 Million
-1,463,025 Reduced 61.84%
902,720 $82.4 Million
Q1 2021

May 14, 2021

BUY
$83.5 - $98.47 $205,827 - $242,728
2,465 Added 0.1%
2,365,745 $202 Million
Q4 2020

Feb 12, 2021

BUY
$78.07 - $94.43 $35.5 Million - $43 Million
455,234 Added 23.86%
2,363,280 $223 Million
Q3 2020

Nov 13, 2020

BUY
$82.14 - $91.0 $13.8 Million - $15.3 Million
167,613 Added 9.63%
1,908,046 $166 Million
Q2 2020

Aug 14, 2020

BUY
$80.93 - $91.1 $176,427 - $198,598
2,180 Added 0.13%
1,740,433 $152 Million
Q1 2020

May 15, 2020

SELL
$70.67 - $99.01 $12.3 Million - $17.3 Million
-174,382 Reduced 9.12%
1,738,253 $143 Million
Q4 2019

Feb 18, 2020

BUY
$84.35 - $95.37 $323,819 - $366,125
3,839 Added 0.2%
1,912,635 $181 Million
Q3 2019

Nov 14, 2019

BUY
$85.54 - $94.26 $572,005 - $630,316
6,687 Added 0.35%
1,908,796 $166 Million
Q2 2019

Aug 14, 2019

BUY
$75.4 - $92.8 $26.5 Million - $32.7 Million
352,024 Added 22.71%
1,902,109 $174 Million
Q1 2019

May 15, 2019

BUY
$75.32 - $86.15 $75 - $86
1 Added 0.0%
1,550,085 $149 Million
Q3 2018

Nov 14, 2018

SELL
$66.94 - $77.43 $200 - $232
-3 Reduced -0.0%
1,550,084 $134 Million
Q2 2018

Aug 14, 2018

BUY
$64.91 - $73.36 $4,608 - $5,208
71 Added 0.0%
1,550,087 $117 Million
Q1 2018

May 15, 2018

SELL
$70.39 - $84.15 $49.9 Million - $59.6 Million
-708,499 Reduced 31.37%
1,550,016 $125 Million
Q3 2017

Nov 14, 2017

BUY
$74.14 - $77.27 $167 Million - $175 Million
2,258,515
2,258,515 $194 Million

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $213B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.